Effect Of Zinc Supplementation On Physical And Psychological Symptoms, Biomarkers Of Inflammation, Oxidative Stress, And Brain-Derived Neurotrophic Factor In Young Women With Premenstrual Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
|Values||Physical symptoms. Mean + SD. Placebo: before 0.47 ± 0.31, after 0.45 ± 0.3. Zinc: before 0.66 ± 0.62, after 0.32 ± 0.29. Psychological symptoms: Placebo: before 0.47 ± 0.29, after 0.48 ± 0.4. Intervention: before 0.62 ± 0.43, after 0.31 ± 0.36.|
|Trial Design||Randomized trial|
|Trial Length||1-6 months|
|Number of Subjects||60|
|Age Range||18-29, 30-44|
In a randomized, double-blind, placebo-controlled trial, 60 women with premenstrual syndrome were allocated to take 30 mg of zinc gluconate or placebo for 12 weeks.
At the end of 12 weeks, the average score for psychological and physical symptoms improved considerably in the zinc group but not the placebo group. Additionally, the zinc group saw a greater increase in BDNF and total antioxidant capacity, and greater decrease in hs-CRP.